Industry News

17 April 2026

Piramal Critical Care has successfully closed the acquisition of Kenalog

Kenalog® is a well-established injectable therapy with a long-standing legacy in the treatment of inflammatory conditions, marketed across 15 countries under trusted brands including Kenalog®, Kenacort®, Trigon®, and Adcortyl®.

15 April 2026

Eli Lilly announced results of Jaypirca (pirtobrutinib)

Eli Lilly and Company announced positive topline results from the Phase 3 BRUIN CLL-322 trial of Jaypirca (pirtobrutinib), a non-covalent (reversible) Bruton tyrosine kinase (BTK) inhibitor, plus venetoclax and rituximab versus venetoclax and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). Treatment in both study arms was administered for up to two years, after which patients do not take any CLL therapy until their disease progresses.

15 April 2026

Johnson & Johnson Highlights Favorable 12-Month Interim Results for the VARIPULSE Platform at EHRA 2026

Johnson & Johnson today announced favorable 12-month interim effectiveness and safety results from VARIPURE, the largest prospective post-market follow-up study evaluating first-time pulsed field ablation (PFA) using the VARIPULSE Platform. The data were presented at the PFA Summit during the 2026 European Heart Rhythm Association (EHRA) Annual Meeting in Paris and simultaneously published in Europace.

10 April 2026

Lupin announces approval of Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the USA

Lupin Limited announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets, 5 mg/500 mg, 5 mg/1,000 mg, 10 mg/500 mg, 10 mg/1,000 mg.

10 April 2026

Amgen announced results from a Phase 3 trial of TEPEZZA

Amgen announced positive topline results from a Phase 3 trial of TEPEZZA (teprotumumab-trbw) administered by subcutaneous injection via an on-body injector (OBI) in participants with moderate-to-severe active Thyroid Eye Disease

27 March 2026

Novo Nordisk : Awiqli® approved in the USA

Novo Nordisk announced that the US Food and Drug Administration (FDA) has approved Awiqli® (insulin icodec-abae) injection 700 units/mL, the first and only once-weekly, long-acting basal insulin, indicated as an adjunct to diet and exercise to improve glycaemic control (blood sugar) in adults living with type 2 diabetes.

18 March 2026

Zydus Lifesciences & Torrent Pharmaceuticals Partner to Co-Market Semaglutide in India

Zydus Lifesciences Limited an innovation-led global life-sciences company and Torrent Pharmaceuticals Limited a specialty-focused global pharmaceutical company, have entered into a Licensing and Supply Agreement to co-market Semaglutide Injection in the Indian market.

5 March 2026

Moderna Settles Vaccine Patent Dispute with 950 Million USD Deal

Biotechnology company Moderna has announced a major settlement to resolve global patent litigation with Arbutus Biopharma Corporation and Genevant Sciences GmbH over technology used in its mRNA vaccines. The agreement settles all ongoing lawsuits worldwide related to the companies’ disputes.

5 March 2026

Sanofi’s rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease

The Ministry of Health, Labour and Welfare (MHLW) in Japan has granted orphan drug designation to rilzabrutinib, a novel, oral, reversible covalent Bruton’s tyrosine kinase (BTK) inhibitor, for IgG4-related disease (IgG4-RD).